Very recent evidence suggests that, within the broad spectrum of cardiovascular diseases, FGF-23 might be a much stronger predictor of incident heart failure events rather than of atherosclerotic vascular events, both among CKD patients, [10,11] and among subjects with a preserved renal function [15]. Here, FGF23 is linked to chronic kidney disease.